Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Amgen, Inc. and Takeda Oncology
How Can We Be More Strategic in Treatment Planning for Patients with ALL?
Release Date: September 9, 2021
Expiration Date: September 9, 2022
Identification of new cytogenetic and molecular abnormalities is leading to great progress in understanding the pathophysiology of acute lymphoblastic leukemia (ALL). The addition of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, novel immune therapies, and chimeric antigen receptor (CAR) T-cell therapy to the treatment landscape has resulted in improved clinical outcomes and more individualized therapeutic regimens based upon patient characteristics, including genetic mutations and previous lines of therapy.
This symposium focuses on the practical aspects of strategically planning management of patients with ALL from front-line treatment to management of relapsed/refractory disease. In addition, it puts recent clinical trial data into a practical, clinical context. The program includes a review of current recommendations regarding testing for minimal residual disease and case presentations by expert faculty, who review treatment selection and sequencing.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Inc. and Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with ALL. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of ALL will be invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Develop individualized treatment strategies for adults and pediatric patients with ALL based on cytogenetic and immunophenotypic characteristics.
- Assess the clinical utility of minimal residual disease assessment and its role in determining prognosis and planning treatment for adults, young adults, and adolescents given a diagnosis of ALL.
- Evaluate the efficacy and safety of current and emerging therapies for ALL.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Disclosures: Grant Research Support: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Pfizer, Spectrum Pharmaceutical, Takeda Pharmaceutical.
Associate Attending Physician,
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Genentech, Amgen, Servier, Incyte; Consultant: Amgen, Novartis, Servier, Kite Pharma, AstraZeneca, Incyte, Takeda, Allogene, Autolus, Intellia
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington School of Medicine
Disclosures: Grant/Research Support: Novartis Pharmaceuticals; Consultant: Amgen, Bristol Myers Squibb, Cepheid, Genentech, Novartis Pharmaceuticals, Takeda Pharmaceutical.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.